Erlotinib 150mg Tablets

Erlotinib 150mg Tablets is a highly potent, first-generation tyrosine kinase inhibitor (TKI) designed to target the Epidermal Growth Factor Receptor (EGFR) in specific types of non-small cell lung cancer (NSCLC) and pancreatic cancer. This medication works as a reversible ATP-competitive inhibitor. In malignant cells, the EGFR pathway is often mutated or overexpressed, leading to a constant “on” signal that tells the cell to divide, survive, and spread. Erlotinib binds specifically to the intracellular tyrosine kinase domain of the EGFR, physically blocking the binding of ATP. Without ATP, the receptor cannot undergo autophosphorylation, effectively silencing the downstream signaling cascades such as the MAPK and PI3K/AKT pathways. This interruption halts the cell cycle and induces apoptosis (cell death) in tumor cells that are “addicted” to EGFR signaling. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for personalized oncology, offering a targeted alternative to traditional cytotoxic chemotherapy.

The 150mg tablet is the standard adult daily dose for the treatment of NSCLC. A critical pharmacokinetic requirement for this medication is its administration on an empty stomach—specifically, at least 1 hour before or 2 hours after food. This is because food can significantly and unpredictably increase the drug’s bioavailability, potentially leading to increased toxicity. The 150mg strength is optimized to maintain therapeutic plasma levels above the minimum inhibitory concentration throughout a 24-hour cycle, ensuring constant pressure on the tumor’s growth signals. Because it is metabolized by the liver (primarily CYP3A4), the 150mg dose serves as a baseline that can be adjusted downward if patients experience severe side effects or are taking interacting medications.

Indications and Uses of Erlotinib 150mg Tablets

Erlotinib 150mg Tablets is commonly prescribed for the specialized management of the following malignancies:

• Metastatic NSCLC with EGFR Mutations: It is indicated as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
• Maintenance Therapy: It is used as a single-agent maintenance treatment in patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
• Advanced Pancreatic Cancer: In combination with gemcitabine, it is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Key Features of Erlotinib 150mg Tablets

• Targeted EGFR Blockade: The primary feature of Erlotinib 150mg Tablets is its high affinity for mutated EGFR, allowing for a more focused attack on cancer cells compared to broad chemotherapy.
• Oral Bioavailability: As an oral medication, it offers patients the convenience of at-home therapy, avoiding the need for frequent clinical infusions.
• ATP-Competitive Mechanism: It effectively out-competes cellular ATP to shut down receptor signaling quickly after administration.
• 150mg Standard Unit: This strength is the clinically validated dose for maximum efficacy in lung cancer, providing a simple once-daily regimen.
• Proven Survival Benefit: Clinical data shows that in patients with sensitizing EGFR mutations, this treatment significantly extends progression-free survival.

Storage for Erlotinib 150mg Tablets

To preserve the pharmacological stability and ultimate potency of the active ingredients, Erlotinib 150mg Tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the tablets in their original light-resistant container to protect them from environmental degradation. Avoid storing the medication in humid environments like bathrooms. For maximum safety, always store Erlotinib 150mg Tablets in a secure, high location that is strictly out of the reach and sight of children and pets.

Safety Warnings for Erlotinib 150mg Tablets

The administration of Erlotinib 150mg Tablets is frequently associated with Dermatologic Toxicity. An acneiform rash is a common mechanistic side effect; while uncomfortable, it is often viewed by clinicians as a biomarker that the drug is effectively hitting its target.

Hepatotoxicity: Periodic monitoring of liver function tests (ALT, AST, and bilirubin) is mandatory, especially in patients with pre-existing hepatic impairment. Gastrointestinal Perforation: Although rare, the risk of “holes” in the GI tract exists and requires immediate medical attention if severe abdominal pain occurs. Interstitial Lung Disease (ILD): Rare but potentially fatal lung inflammation can occur; patients must report new or worsening shortness of breath or cough immediately.

Drug Interactions: Smoking significantly decreases the blood levels of Erlotinib (by inducing enzymes), often requiring a higher dose; conversely, strong CYP3A4 inhibitors can spike levels dangerously. Erlotinib 150mg Tablets can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and the empty-stomach dosing rule, healthcare providers can safely maximize the therapeutic benefits of Erlotinib 150mg Tablets.